Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review

Critical Reviews in Oncology/Hematology

Volumn 94, Issue 2, 2015, Pages 201-212

  Wang, Xiao Jun ^a,b   Lopez, Shaun Eric ^a   Chan, Alexandre ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Cost; Economic burden; Febrile neutropenia; Fever; Lymphoma; Neutropenia; Systematic review

Indexed keywords

COMORBIDITY; COST OF ILLNESS; FEBRILE NEUTROPENIA; HEALTH CARE PERSONNEL; HOSPITAL PATIENT; HOSPITALIZATION COST; HUMAN; INCIDENCE; LYMPHOMA; MORBIDITY; MORTALITY; OUTPATIENT; PATIENT CARE; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COMPLICATION; ECONOMICS; META ANALYSIS;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA; COST OF ILLNESS; HUMANS; LYMPHOMA;

EID: 84926078684     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2014.12.011     Document Type: Review

References (46)

1. Ng J.H., Ang X.Y., Tan S.H., Tao M., Lim S.T., Chan A. Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. Acta Haematol 2011, 125:107-114.
2. Pettengell R., Bosly A., Szucs T.D., et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol 2009, 144:677-685.
3. Aapro M.S., Bohlius J., Cameron D.A., et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer (Oxf, Engl: 1990) 2011, 47:8-32.
4. Wong M., Jin J., Tan M.H., et al. Prospective audit of post-chemotherapy febrile neutropenia in patients with solid cancer and lymphoma in two Singaporean cancer centres. Ann Acad Med Singap 2012, 41:287-293.
5. Pettengell R., Johnsen H.E., Lugtenburg P.J., et al. Impact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphoma. Support Care Cancer 2012, 20:647-652.
6. Tarricone R. Cost-of-illness analysis. What room in health economics?. Health Policy (Amst, Neth) 2006, 77:51-63.
7. Hodgson T.A., Meiners M.R. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Meml Fund Q Health Soc 1982, 60:429-462.
8. Segel J.E. Cost-of-illness studies-a primer 2006, 1-39. RTI-UNC Center of Excellence in Health Promotion Economics.
9. Ament A., Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy (Amst, Neth) 1993, 26:29-42.
10. Zhou Y.P., Jin J., Ding Y., et al. Direct costs associated with febrile neutropenia in inpatients with hematological diseases in Singapore. Support Care Cancer 2014, 22(6):1447-1451.
11. Hendricks A.M., Loggers E.T., Talcott J.A. Costs of home versus inpatient treatment for fever and neutropenia: analysis of a multicenter randomized trial. J Clin Oncol 2011, 29:3984-3990.
12. Weycker D., Malin J., Edelsberg J., Glass A., Gokhale M., Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol 2008, 19:454-460.
13. Karen R. Measuring and estimating costs. Essentials of pharmacoeconomics 2009, 250. Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA.
14. McLinden T. A scoping review of component costs of foodborne illness and analysis of the association between study methodologies and component costs to the cost of a foodborne illness 2013.
15. Liou S.Y., Stephens J.M., Carpiuc K.T., Feng W., Botteman M.F., Hay J.W. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig 2007, 27:381-396.
16. Lathia N., Mittmann N., DeAngelis C., et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer 2010, 116:742-748.
17. Chan A., Wong Q.X., Ali M.K., Wong M., Hsu L.Y. Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. Support Care Cancer 2014, 22:1105-1112.
18. Kriza C., Emmert M., Wahlster P., Niederlander C., Kolominsky-Rabas P. Cost of illness in colorectal cancer: an international review. Pharmacoeconomics 2013, 31:577-588.
19. Larg A., Moss J.R. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics 2011, 29:653-671.
20. Stuhldreher N., Konnopka A., Wild B., et al. Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review. Int J Eat Disord 2012, 45:476-491.
21. Dulisse B., Li X., Gayle J.A., et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ 2013, 16:720-735.
22. Livingston P.M., Craike M., Slavin M. Clinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in Victoria Australia. Oncologist 2012, 17:998-1004.
23. Mayordomo J.I., Lopez A., Vinolas N., et al. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain. Curr Med Res Opin 2009, 25:2533-2542.
24. Bennett C.L., Calhoun E.A. Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients. Oncologist 2007, 12:478-483.
25. Michels S.L., Barron R.L., Reynolds M.W., Smoyer Tomic K., Yu J., Lyman G.H. Costs associated with febrile neutropenia in the US. Pharmacoeconomics 2012, 30:809-823.
26. Weycker D., Danel A., Marciniak A., Bendall K., Lipsitz M., Pettengell R. Economic costs of chemotherapy-induced febrile neutropenia among patients with non-Hodgkin's lymphoma in European and Australian clinical practice. BMC Cancer 2012, 12:362.
27. Jakubowski E.B.R., Chambers G.R. Health care systems in the EU a comparative studyPN European Parliament 1998, Available from: http://www.europarl.europa.eu/workingpape.
28. RGE Drug pricing: a comparison between Canada and other countries. Toronto, Ontario 2002, Available from: http://www.pmprb-cepmb.gc.ca/english/view.asp?.x=138&mid=90 [accessed 11.02.14].
29. Chang J. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer (Oxf, Engl: 1990) 2000, 36(Suppl. 1):S11-S14.
30. Lyman G.H., Kuderer N.M. Epidemiology of febrile neutropenia. Support Cancer Ther 2003, 1:23-35.
31. Lyman G.H., Morrison V.A., Dale D.C., Crawford J., Delgado D.J., Fridman M. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003, 44:2069-2076.
32. Cosler L.E., Calhoun E.A., Agboola O., Lyman G.H. Effects of indirect and additional direct costs on the risk threshold for prophylaxis with colony-stimulating factors in patients at risk for severe neutropenia from cancer chemotherapy. Pharmacotherapy 2004, 24:488-494.
33. Chrischilles E., Delgado D.J., Stolshek B.S., Lawless G., Fridman M., Carter W.B. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control 2002, 9:203-211.
34. Birnbaum H.G., Kessler R.C., Lowe S.W., et al. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin 2005, 21:195-206.
35. Rubenstein L.M., Chrischilles E.A., Voelker M.D. The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997, 12:486-498.
36. Chan A., Lee C.P., Chiang J., Ng R. Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. Support Care Cancer 2013, 21:2137-2143.
37. Klastersky J., Paesmans M., Rubenstein E.B., et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000, 18:3038-3051.
38. Cooper K.L., Madan J., Whyte S., Stevenson M.D., Akehurst R.L. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011, 11:404.
39. Kuderer N.M., Dale D.C., Crawford J., Lyman G.H. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007, 25:3158-3167.
40. Aarts M.J., Grutters J.P., Peters F.P., et al. Cost effectiveness of primary pegfilgrastim prophylaxis in patients with breast cancer at risk of febrile neutropenia. J Clin Oncol 2013, 31:4283-4289.
41. Lathia N., Isogai P.K., De Angelis C., et al. Cost-effectiveness of filgrastim and pegfilgrastim as primary prophylaxis against febrile neutropenia in lymphoma patients. J Natl Cancer Inst 2013, 105:1078-1085.
42. Welte K. G-CSF: filgrastim, lenograstim and biosimilars. Expert Opin Biol Ther 2014, 14:983-993.
43. Waller C.F., Semiglazov V.F., Tjulandin S., Bentsion D., Chan S., Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010, 33:504-511.
44. Gatzemeier U., Ciuleanu T., Dediu M., Ganea-Motan E., Lubenau H., Del Giglio A. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009, 4:736-740.
45. Drummond M.F.S.M., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for the economic evaluation of health care programmes 2005, Oxford University Press. 3rd ed.
46. Ruof J., Hulsemann J.L., Mittendorf T., et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003, 62:544-549.